Wells Fargo has lowered its price target for Insmed (INSM) from $234.00 to $208.00 while maintaining an “Overweight” rating. This adjustment comes amidst other recent analyst updates for INSM from firms like Morgan Stanley, Barclays, Roth Capital, RBC Capital, and UBS, reflecting varied assessments of the biopharmaceutical company’s future performance. Despite the reduced target, the average analyst price target for INSM suggests a significant upside from its current price, although GuruFocus’ GF Value estimates a potential downside.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Wells Fargo Lowers Price Target for Insmed (INSM) Amid Overweight Rating | INSM Stock News
Wells Fargo has lowered its price target for Insmed (INSM) from $234.00 to $208.00 while maintaining an “Overweight” rating. This adjustment comes amidst other recent analyst updates for INSM from firms like Morgan Stanley, Barclays, Roth Capital, RBC Capital, and UBS, reflecting varied assessments of the biopharmaceutical company’s future performance. Despite the reduced target, the average analyst price target for INSM suggests a significant upside from its current price, although GuruFocus’ GF Value estimates a potential downside.